Mark Bonyhadi
Direttore/Membro del Consiglio presso TC BIOPHARM (HOLDINGS) PLC
Patrimonio netto: - $ in data 31/05/2024
Profilo
Mark L.
Bonyhadi is an Independent Director at TC Biopharm (Holdings) Plc.
He previously served as the Chairman of the American Society of Gene & Cell Therapy.
Mark also held positions as the Director-Global Business Development at Life Technologies Ltd.
from 2006 to 2013, Vice President-Research & Development at Xcyte Therapies, Inc. from 1997 to 2006, Vice President-Research & Head-Academic Affairs at Juno Therapeutics, Inc. from 2013 to 2018, and as a Senior Advisor at Qiming US Ventures Management, LLC from 2018 to 2022.
He has also worked as a Senior Scientist at Systemix, Inc. Mark's educational background includes an undergraduate degree from The Reed Institute in 1982 and a doctorate from the University of California, Berkeley in 1990.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 27/05/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Mark Bonyhadi
| Società | Posizione | Inizio |
|---|---|---|
| TC BIOPHARM (HOLDINGS) PLC | Direttore/Membro del Consiglio | 22/02/2022 |
Precedenti posizioni note di Mark Bonyhadi
| Società | Posizione | Fine |
|---|---|---|
Qiming US Ventures Management, LLC
 Qiming US Ventures Management, LLC Investment ManagersFinance Qiming US Ventures Management LLC (Qiming Venture Partners) is a venture capital subsidiary of Qiming Venture Partners Ltd founded in 2017 by Mark D. McDade and Gary Edward Rieschel. The firm is headquartered in Cambridge, Massachusetts. | Consulente / Consigliere | 31/12/2022 |
Systemix, Inc.
 Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Direttore Tecnico/Scientifico/R&S | 12/10/2021 |
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | 01/01/2018 |
Life Technologies Ltd.
 Life Technologies Ltd. BiotechnologyHealth Technology Life Technologies Ltd. engages in scientific and medical activities. The company was founded on May 13, 1983 and is headquartered in Paisley, the United Kingdom. | Corporate Officer/Principal | 01/01/2013 |
| Xcyte Therapies, Inc. | Direttore Tecnico/Scientifico/R&S | 30/03/2006 |
Formazione di Mark Bonyhadi
| The Reed Institute | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| TC BIOPHARM (HOLDINGS) PLC | Health Technology |
| Aziende private | 6 |
|---|---|
| Xcyte Therapies, Inc. | Health Technology |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Life Technologies Ltd.
Life Technologies Ltd. BiotechnologyHealth Technology Life Technologies Ltd. engages in scientific and medical activities. The company was founded on May 13, 1983 and is headquartered in Paisley, the United Kingdom. | Health Technology |
Qiming US Ventures Management, LLC
Qiming US Ventures Management, LLC Investment ManagersFinance Qiming US Ventures Management LLC (Qiming Venture Partners) is a venture capital subsidiary of Qiming Venture Partners Ltd founded in 2017 by Mark D. McDade and Gary Edward Rieschel. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Systemix, Inc.
Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Health Services |
American Society of Gene & Cell Therapy
 American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay. | Commercial Services |
- Borsa valori
- Insiders
- Mark Bonyhadi
